Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medical technology company HeraMED will partner with German midwife service provider, Kinderheldin, to add a telehealth service to its portfolio
  • The company’s HeraBEAT device allows expecting mothers to monitor their baby’s heart beat using an ultrasonic monitor
  • The agreement will see the release of HeraBEAT plus, that will provide online midwife support to mothers using the device
  • Existing partner Duttenhofer will also be involved in the two-year agreement
  • Shares are down 4.08 per cent and trading for 23.5 cents each

Medical technology company HeraMED will partner with midwife service provider Kinderheldin to launch a telehealth service.

Kinderheldin, a German company, already has an online platform where expecting parents can talk to midwives.

The new partnership will see HeraMED’s foetal heartbeat monitor, HeraBEAT, connected to Kenderheldin’s online midwife service. The telehealth feature will be incorporated into a new device, the HeraBEAT Plus and launched in Germany.

Kinderheldin’s midwives will be able to access the heartbeat information via the platform to provide more informed and immediate advice.

Initially, the telehealth feature will be complimentary and then be operated as a subscription service.

In addition to the two-year agreement with Kinderheldin, HeraMED has tabled plans for the two companies to commence discussion regarding the product with both healthcare providers and insurance companies in Germany. Kinderheldin is well connected with over 50 insurance company partnerships and 5 major hospital partnerships.

Existing partner Duttenhofer Group will also be part of the HearBEAT Plus collaboration. In August this year, HeraMED announced an agreement with Duttenhofer to distribute HeraBEAT in Germany, Austria and Switzerland.

HeraMED shares are down 4.08 per cent and trading for 23.5 cents each at 2:20 pm.

HMD by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.